K. Bielosludtseva (Dniepropetrovsk, Ukraine), C. Summers (Cambridge (Cambridgeshire), United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Hematological parameters- as mortality predictors in COVID-19 patients
C. Cojocaru (Iasi, Romania), E. Cojocaru (Iasi , Romania)
|   |
Ferritin versus D-dimer:comparison of prognostic roles in COVID-19 pneumonia
O. Myronenko (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), L. Konopkina (Dnipro, Ukraine), O. Plekhanova (Dnipro, Ukraine), M. Krykhtina (Dnipro, Ukraine)
| |
Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia
M. Ghanem (Paris, France), M. Homps-Legrand (Paris, France), L. Morer (Paris, France), T. Goletto (Paris, France), J. Frija (Paris, France), C. Bancal (Paris, France), M. Hurtado-Nedelec (Paris, France), M. Jaillet (Paris, France), A. Mailleux (Paris, France), C. Neukirch (Paris, France), R. Borie (Paris, France), C. Taille (Paris, France), B. Crestani (Paris, France)
| |
Pathophysiological parameters of microcirculation as determinants of mortality in SARS-CoV-2 pneumonia
F. Sanz Herrero (València, Spain), F. Puchades Gimeno (València, Spain), E. Verdejo Mengual (València, Spain), V. Abril López De Medrano (València, Spain), S. Carrascosa García (València, Spain), J. Mateo González (València, Spain), A. Lluch Bisbal (València, Spain), N. Carrión Collado (València, Spain), A. González Cruz (València, Spain), M. García Deltoro (València, Spain), E. Fernández Fabrellas (València, Spain)
| |
Indicators of systemic inflammation in critically ill patients with COVID-19.
R. Abdullaev (Moscow, Russian Federation), O. Komissarova (Moscow, Russian Federation), Y. Berezovskiy (Moscow, Russian Federation), E. Gretsov (Moscow, Russian Federation)
| |
Indicators of hemostasis and fibrinolysis systems in critically ill patients with COVID-19.
R. Abdullaev (Moscow, Russian Federation), O. Komissarova (Moscow, Russian Federation), Y. Berezovakiy (Moscow, Russian Federation), Y. Gretsov (Moscow, Russian Federation)
| |
Admission clinical parameters in predicting in-hospital mortality in COVID-19
D. Mudawi (Manchester, United Kingdom), R. Wang (Manchester, United Kingdom), K. Heyes (Manchester, United Kingdom), R. Niven (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom)
| |
Correlation of renal impairment with biochemical and radiological findings, and clinical outcome in COVID-19 pneumonia patients
I. Papadaki (Athens, Greece), D. Papadopoulos (Athens, Greece), G. Dendrinou (Athens, Greece), T. Tambakis (Athens, Greece), V. Gkogkos (Athens, Greece), S. Kanellas (Athens, Greece), S. Myrotheou (Athens, Greece), I. Dura (Athens, Greece), M. Christodoulou (Athens, Greece), T. Triantafyllou (Athens, Greece), K. Zeibecoglou (Athens, Greece)
| |
The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
C. Cilloniz Campos (Barcelona, Spain), H. Peroni (Buenos Aires, Argentina), C. Domingo (Barcelona, Spain), R. Muñoz (Barcelona, Spain), J. Bedini (Barcelona, Spain), A. Soriano (Barcelona, Spain), A. Torres (Barcelona, Spain)
| |
The best coagulation marker for prediction of COVID-19 pneumonia progression.
M. Krykhtina (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), L. Konopkina (Dnipro, Ukraine)
| |
Association between creatine kinase level and mortality in high-risk patients with COVID-19
A. Kitbalian (Moscow, Russian Federation), M. Brovko (Moscow, Russian Federation), L. Akulkina (Moscow, Russian Federation), P. Potapov (Moscow, Russian Federation), A. Moiseev (Moscow, Russian Federation), A. Schepalina (Moscow, Russian Federation), A. Yakovleva (Moscow, Russian Federation), V. Sholomova (Moscow, Russian Federation), S. Moiseev (Moscow, Russian Federation)
| |
Lymphocyte-to-monocyte ratio (LMR) as a predictor of Covid-19 pneumonia progression
D. Koval (Dnipropetrovsk, Ukraine), T. Pertseva (Dnipropetrovsk, Ukraine), L. Konopkina (Dnipropetrovsk, Ukraine), K. Bielosludtseva (Dnipropetrovsk, Ukraine), M. Krykhtina (Dnipropetrovsk, Ukraine)
| |
What is the best biomarker of COVID-19 pneumonia progression?
K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), T. Kirieieva (Dnipro, Ukraine), B. Basina (Dnipro, Ukraine), N. Krabchenko (Dnipro, Ukraine), M. Krykhtina (Dnipro, Ukraine)
| |
Platelet-to-lymphocyte ratio (PLR) as a predictor of Covid-19 pneumonia progression
D. Koval (Dnipropetrovsk, Ukraine), L. Konopkina (Dnipropetrovsk, Ukraine), K. Bielosludtseva (Dnipropetrovsk, Ukraine), M. Krykhtina (Dnipropetrovsk, Ukraine)
| |
C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia?
B. Basina (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), T. Kirieieva (Dnipro, Ukraine), M. Krykhtina (Dnipro, Ukraine), N. Kravchenko (Dnipro, Ukraine)
| |
Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection
S. Sutharsan (Essen, Germany), M. Berger (Essen, Germany), J. Andrä (Essen, Germany), L. Jehn (Essen, Germany), C. Taube (Essen, Germany), T. Brenner (Essen, Germany), S. Kattner (Essen, Germany), A. Limmer (Essen, Germany), F. Bonella (Essen, Germany)
| |
ISTH Criteria for Disseminated Intravascular Coagulation (DIC) scale, Padua scale, D-dimer or Fibrinogen: what is the best predictor of COVID-19 pneumonia progression?
M. Krykhtina (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), L. Konopkina (Dnipro, Ukraine)
| |
Relation between inflammatory biomarkers and oxygen needs in severe COVID-19 patients
S. Essebaa (Ariana, Tunisia), S. Daboussi (Ariana, Tunisia), S. Mhamdi (Ariana, Tunisia), N. Guediri (Ariana, Tunisia), I. Mejri (Ariana, Tunisia), C. Aichaouia (Ariana, Tunisia), Z. Moatemri (Ariana, Tunisia), M. Khadhraoui (Ariana, Tunisia)
| |
The prognostic value of procalcitonin in patients with hypoxemic COVID 19 pneumonia.
I. Mejri Ep Ajili (Tunis, Tunisia), N. Boubaker (Tunis, Tunisia), H. Kchouk (Tunis, Tunisia), S. Mhamdi (Tunis, Tunisia), S. Daboussi (Tunis, Tunisia), C. Aichaouia (Tunis, Tunisia), Z. Moatemri (Tunis, Tunisia), M. Khadhraoui (Tunis, Tunisia)
| |
Differences in inflammation biomarkers among COVID-19 and Non-COVID-19 pneumonia.
A. REZOLA CARASUSAN (Barakaldo, Spain), L. Serrano Fernandez (Barakaldo, Spain), L. Ruiz Iturriaga (Barakaldo, Spain), E. Echevarria Guerrero (Barakaldo, Spain), B. Gonzalez Quero (Barakaldo, Spain), J. Andia Iturrate (Barakaldo, Spain), E. Garay Llorente (Barakaldo, Spain), J. Solorzano Santobeña (Barakaldo, Spain), I. Gonzalez Muñoz (Barakaldo, Spain), R. Zalacain Jorge (Barakaldo, Spain)
| |